fight against mesothelioma asbestos cancer little progress

Researchers at Oncolytics Biotech Inc. to present at the annual meeting of iSBTC positive results for the combination of REOLYSIN (R) and docetaxel

Calgary, Canada, November 3 - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that they have achieved in their UK clinical trial of combination REOLYSIN (R) and docetaxel for patients with advanced cancer positive interim results.
At the annual meeting of the International Society for Biological Therapy of Cancer (iSBTC) (= International Society for Biological Cancer Therapy) 1 November 2008, before Prof. Hardev Pandha of Britain's Royal Surrey Hospital the results. The conference took place between 31 October and the second November 2008 in San Diego, California, instead.
Fourteen patients were previously tested with gradually increasing doses of the study, and eleven patients to be evaluated for their response in terms. The detailed results of this are summarized in the following table:
   -------------------------------------------------- -----------------------
   Primary tumor-dose cycles of REOLYSIN Best Response
                                TCID (50)
   -------------------------------------------------- -----------------------
   Breast 1x10 (10) 8 PR
                                                       CR in the liver
   -------------------------------------------------- -----------------------
   Stomach 3x10 (10) 8 (x) PR
                                                       32% decrease in
                                                       Lymph node
   -------------------------------------------------- -----------------------
   Mesothelioma 1x10 (10) 6 Light response
                                                       23% decrease in
                                                       Lymph node
   -------------------------------------------------- -----------------------
   Prostate 3x10 (9) 6 SD in Scans
                                                       30% decrease
                                                       in PSA
   -------------------------------------------------- -----------------------
   Squamous 3x10 (9) 3 Low
                                                       Address
                                                       26% decrease in
   Head and neck lymph nodes
   -------------------------------------------------- -----------------------
   Unknown 3x10 (9) 6 SD
   -------------------------------------------------- -----------------------
   Pancreas 3x10 (10) 6 (x) SD
   -------------------------------------------------- -----------------------
   Prostate 3x10 (10) 5 (x) SD
   -------------------------------------------------- -----------------------
   Prostate 3x10 (10) 5 SD
   -------------------------------------------------- -----------------------
   Melanoma 1x10 (10) 4 SD
   -------------------------------------------------- -----------------------
   Pancreas 3x10 (10) 2 SD, but
   progressed clinically
   -------------------------------------------------- -----------------------
    (X) patients still participating in the study. = CR (complete
        response) complete response, PR = (partial response)
        partial response, SD = (stable disease) stabilized disease
"These are extraordinary results for a Phase I trial," said Dr. Brad Thompson, President and CEO of Oncolytics. "In these patients a stabilization of the tumor or even to achieve even more, is highly unusual."
The trial (REO 010) is comprised of two components. The first is an open-label, dose-escalating, non-randomized study of REOLYSIN (R), which is administered every three weeks intravenously with docetaxel. This section of the study, which was completed in August 2008, the patients were given together with increased doses of intravenous REOLYSIN (R) is the standard-dose docetaxel. The second component of the study include the inclusion of nine additional patients who received the highest dose of REOLYSIN (R) in combination with standard-dose docetaxel. The patients in this study can receive up to eight treatment cycles.
In question are those patients with advanced or metastatic solid tumors, including diagnosed cancer in the upper gastrointestinal tract or bladder, lung, prostate cancers were who were refractory to standard therapy (have not responded) or for which there is no curative therapy is standard. The main objective of this study is to determine the maximum tolerated dose or Maximum Tolerated Dose (MTD), Dose-dependent toxicity or dose-limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN (R) when administered in combination with docetaxel. Among the secondary objectives include the assessment of the immune response to the combination of drugs, the body's response to the drug combination compared to chemotherapy as a single measure, and any evidence of antitumor activity.
The poster can today be found on the Oncolytics website at from the main site.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company based in Calgary, specializing in the development of oncolytic viruses as potential agents for cancer therapy.
Oncolytics' clinical program includes the various human I/II- phase and phase II trials, which is used REOLYSIN (R), its proprietary formulation of the human reovirus, alone or in combination with radiotherapy or chemotherapy. For further information about Oncolytics, please visit the website.
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. On forward-looking statements, including the importance of this conference with respect to REOLYSIN (R) presented material, the Company's expectations for the results of studies on REOLYSIN (R), the analysis of the results of the Phase I_Studie by the company and the the Company believes the potential of REOLYSIN (R) in cancer therapy included both known and unknown risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources for research and development, the efficacy of REOLYSIN (R) in cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to REOLYSIN (R) successfully to market uncertainties associated with research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes in economic conditions. We recommend investors to view the quarterly and annual filings with the Canadian and U.S. securities regulators, to learn more about the risks and uncertainties associated with forward-looking statements on. Investors are cautioned against placing on the forward-looking statements are an inappropriate significance. The Company does not intend to update these forward-looking statements, unless it is prescribed by law.

Legal assistance in case of asbestos scandal in Italy

Suva flashes from the Federal Court
Legal assistance in case of asbestos scandal in Italy to

Switzerland agrees to grant the Italian law enforcement authorities in the asbestos scandal against the will of the Suva legal assistance. This was decided by the Federal Court. It's about numerous dossiers Suva Italian Eternit workers who had come into contact with asbestos.
(AP) Prosecutors in Turin has for many years a criminal investigation against an unknown perpetrator because of multiple manslaughter. It is about Italians, who worked at Eternit AG and Italy in a tumor caused by asbestos - have died - a so-called mesothelioma. The Italian authorities had first arrived in 2001 with a request for legal assistance from Switzerland.

In January this year ordered the interrogation office Glarus, the publication of numerous documents to the Italian authorities. These included documents from the Eternit AG Suva and 196 dossiers of employees, of which 62 ill and 16 died in Italy. The Italians worked 1950-1993 at Eternit AG. Both the Eternit AG and Suva had set itself against the legal aid to defend, but flashed from the Canton of Glarus Court.

The complaints to the Federal Court were unsuccessful. The Lausanne judges came to the conclusion that the award is contrary to the legal assistance from a purely legal point of view no obstacle.

Suva had argued in Lausanne in particular, the legal aid technique constitutes a pure fishing expedition desire - a so-called fishing expedition - is the Italian authorities and ultimately aims to review the activities of Suva. The latter, however, stand only to the Federal Office of Public Health or the Federal Council and not "foreign judges". Legal aid therefore contrary to the "ordre public".

Whether the "public policy" is injured and precludes the disclosure of the documents to the Italian investigation authorities, however, decided in another proceeding. A similar complaint was filed, Suva in January 2006 at the Justice and Police Department. After completion of the now by the Federal Court proceedings are determined, the Department and, if found to have about the Federal Council.